Co-Authors
This is a "connection" page, showing publications co-authored by Mingfeng Han and Xiuyong Li.
Connection Strength
0.907
-
Differentially expressed immune response genes in COVID-19 patients based on disease severity. Aging (Albany NY). 2021 03 29; 13(7):9265-9276.
Score: 0.234
-
Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity. Med Microbiol Immunol. 2020 Dec; 209(6):657-668.
Score: 0.225
-
COVID-19 induced liver function abnormality associates with age. Aging (Albany NY). 2020 07 28; 12(14):13895-13904.
Score: 0.224
-
Reply to Wang et al.: Tocilizumab treatment should be used in a timely manner, at suitable dose, and in suitable patients. Proc Natl Acad Sci U S A. 2020 12 08; 117(49):30898-30899.
Score: 0.057
-
Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention. Proc Natl Acad Sci U S A. 2020 12 01; 117(48):30027-30028.
Score: 0.057
-
Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 05 19; 117(20):10970-10975.
Score: 0.055
-
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020 07; 92(7):791-796.
Score: 0.055